Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more
Shanghai Haohai Biological Technology Co. Ltd (5HB) - Net Assets
Latest net assets as of June 2025: €5.88 Billion EUR
Based on the latest financial reports, Shanghai Haohai Biological Technology Co. Ltd (5HB) has net assets worth €5.88 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.19 Billion) and total liabilities (€1.30 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €5.88 Billion |
| % of Total Assets | 81.86% |
| Annual Growth Rate | 8.93% |
| 5-Year Change | 3.19% |
| 10-Year Change | N/A |
| Growth Volatility | 15.3 |
Shanghai Haohai Biological Technology Co. Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Shanghai Haohai Biological Technology Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Haohai Biological Technology Co. Ltd (2016–2024)
The table below shows the annual net assets of Shanghai Haohai Biological Technology Co. Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €5.92 Billion | -1.67% |
| 2023-12-31 | €6.02 Billion | +1.95% |
| 2022-12-31 | €5.90 Billion | -2.61% |
| 2021-12-31 | €6.06 Billion | +5.69% |
| 2020-12-31 | €5.73 Billion | +1.43% |
| 2019-12-31 | €5.65 Billion | +47.40% |
| 2018-12-31 | €3.84 Billion | +13.92% |
| 2017-12-31 | €3.37 Billion | +12.75% |
| 2016-12-31 | €2.99 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Haohai Biological Technology Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 194.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.86 Billion | 51.38% |
| Other Components | €2.71 Billion | 48.62% |
| Total Equity | €5.58 Billion | 100.00% |
Shanghai Haohai Biological Technology Co. Ltd Competitors by Market Cap
The table below lists competitors of Shanghai Haohai Biological Technology Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hainan Shuangcheng Pharmaceut
SHE:002693
|
$234.02 Million |
|
Puma Biotechnology Inc
NASDAQ:PBYI
|
$234.04 Million |
|
Suzhou Yangtze New Materials
SHE:002652
|
$234.06 Million |
|
Zhejiang Shuangyuan Technology Co. Ltd. A
SHG:688623
|
$234.07 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
$233.96 Million |
|
ARES COMM.REAL EST.DL-01
F:41I
|
$233.93 Million |
|
HealthCare Inc
PINK:HLTC
|
$233.93 Million |
|
Deutsche EuroShop AG
PINK:DUSCF
|
$233.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Haohai Biological Technology Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,650,064,000 to 5,575,259,000, a change of -74,805,000 (-1.3%).
- Net income of 420,447,000 contributed positively to equity growth.
- Dividend payments of 259,859,000 reduced retained earnings.
- Share repurchases of 175,354,000 reduced equity.
- New share issuances of 49,451,000 increased equity.
- Other factors decreased equity by 109,490,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €420.45 Million | +7.54% |
| Dividends Paid | €259.86 Million | -4.66% |
| Share Repurchases | €175.35 Million | -3.15% |
| Share Issuances | €49.45 Million | +0.89% |
| Other Changes | €-109.49 Million | -1.96% |
| Total Change | €- | -1.32% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Haohai Biological Technology Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.11x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €20.00 | €2.62 | x |
| 2018-12-31 | €22.57 | €2.62 | x |
| 2019-12-31 | €30.67 | €2.62 | x |
| 2020-12-31 | €30.87 | €2.62 | x |
| 2021-12-31 | €32.50 | €2.62 | x |
| 2022-12-31 | €31.67 | €2.62 | x |
| 2023-12-31 | €32.95 | €2.62 | x |
| 2024-12-31 | €24.19 | €2.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Haohai Biological Technology Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.54%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.69%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.28x
- Recent ROE (7.54%) is below the historical average (7.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 10.50% | 35.84% | 0.23x | 1.27x | €14.65 Million |
| 2017 | 11.64% | 27.69% | 0.33x | 1.27x | €52.36 Million |
| 2018 | 11.48% | 26.82% | 0.35x | 1.23x | €53.39 Million |
| 2019 | 6.80% | 23.24% | 0.26x | 1.13x | €-174.70 Million |
| 2020 | 4.19% | 17.37% | 0.21x | 1.15x | €-319.00 Million |
| 2021 | 6.16% | 20.13% | 0.25x | 1.22x | €-219.11 Million |
| 2022 | 3.27% | 8.58% | 0.31x | 1.25x | €-370.99 Million |
| 2023 | 7.36% | 15.79% | 0.37x | 1.26x | €-148.89 Million |
| 2024 | 7.54% | 15.69% | 0.38x | 1.28x | €-137.08 Million |
Industry Comparison
This section compares Shanghai Haohai Biological Technology Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Haohai Biological Technology Co. Ltd (5HB) | €5.88 Billion | 10.50% | 0.22x | $234.01 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |